The acquisition included the FDA cleared expanding and articulating FLXfit and FLXfit 15 titanium TLIF interbody systems, a range of patents and in-development products that address the expandable interbody and spinal fusion market.

Expanding Orthopedics addresses unmet clinical needs for spine care.

The company is backed by venture funding and has a portfolio of anatomically fit, expandable devices for enhanced stability and fixation through a low profile, minimally invasive approach.

CoreLink CEO Jay Bartling said: “This acquisition provides two key benefits for CoreLink and its customers: a very compelling offering in the growing expandable interbody product category and a portfolio of innovative intellectual property from which we can advance spine care.

“Combining these assets with CoreLink’s unique in-house design and manufacturing capabilities provides tremendous opportunities for us and our business partners.”

FLXfit 15 is a titanium TLIF interbody device compatible with minimally invasive surgery. Once it is placed in the disc space, it can articulate in aiding the placement along the anterior aspect of the apophyseal ring.

It can provide up to 40mm of footprint length along the anterior column.

The anterior height of the device can be continuously expanded by 4mm to provide up to 15° of lordosis.

CoreLink stated that it will offer enhanced support for the existing users of both FLXfit and FLXfit 15 systems, while using its vertical integration to integrate system upgrades for a full commercial re-launch in the third quarter of this year.

CoreLink research and development vice president David Castleman said “This is an exciting time for product development at CoreLink.

“There is great opportunity here to leverage the EOI expandable technology across several product categories, from other interbody applications to pedicle screw solutions.”